#non-Hodgkin's lymphoma

CAR-T Therapy Highly Effective for People with High-Risk Non-Hodgkin Lymphoma

After cancer treatment, many of us need a specialist trained in oncology and survivorship who can coordinate care and improve outcomes.

New data strongly suggest that axi-cel, as this CAR T-cell therapy is often called, can offer real hope for these lymphoma patients.

Breast cancer and lymphoma patients who exercised for just 10 minutes had increased numbers of killer T-cells and natural killer cells.

Palliative care specialists help patients find relief from pain, stress and treatment side effects.

More than 40% of patients treated with the bispecific T-cell engager experienced complete remission.

The overall response rate was 61% for patients treated with the bispecific T-cell engager.

Women with lymphoma who received treatment in the afternoon had lower relapse and mortality rates than those treated earlier in the day.

The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.

Customized T-cell treatment is generally safe for people living with HIV, and outcomes are comparable to those of HIV-negative people.

However, lung cancer incidence among HIV-positive people has fallen over the past two decades.

As the new editor-in-chief of Cancer Health, Trent Straube is honored to amplify stories of survivors, families, advocates and more.

Toby Keith, Robin Roberts, Jeff Bridges and more share their cancer stories.

“This is a very treatable cancer,” says Oscar-winning actress Jane Fonda, who will start chemotherapy for non-Hodgkin lymphoma.

A new report stresses the need for better access to health insurance coverage to improve cancer care and outcomes.